Skye Bioscience, Inc. (NASDAQ: SKYE) AI-Powered Stock Analysis
See how Skye Bioscience, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
SKYE●NASDAQ
HealthcareBiotechnology
$0.28
$0.03(8.17%)
U.S. Market opens in 17h 16m
Skye Bioscience, Inc. (NASDAQ: SKYE) AI-Powered Stock Analysis
See how Skye Bioscience, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerSkye Bioscience, Inc. (NASDAQ: SKYE) Stock Overall Grade
Skye Bioscience, Inc.'s grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Skye Bioscience, Inc.'s overall NASDAQ stock rating.
Forecast
C+Score
52/100Financial Growth
AScore
80/100Fundamental Growth
B+Score
77/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Skye Bioscience, Inc. (NASDAQ: SKYE) AI-Powered Stock Analysis
On the NASDAQ, SKYE demonstrates Good performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (77/100, B+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(NASDAQ: SKYE) Component Analysis Explained
Understand the key factors behind each Skye Bioscience, Inc. (NASDAQ: SKYE) stock grade, including financials, comparisons, and forecasts.